Reply: Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease

Free article

Comment

Yaling Han. J Am Coll Cardiol. 2014.

Free article

. 2014 Jul 22;64(3):332-3.

doi: 10.1016/j.jacc.2014.04.039.

No abstract available

Comment on

Short-term rosuvastatin therapy for prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Han Y, Zhu G, Han L, Hou F, Huang W, Liu H, Gan J, Jiang T, Li X, Wang W, Ding S, Jia S, Shen W, Wang D, Sun L, Qiu J, Wang X, Li Y, Deng J, Li J, Xu K, Xu B, Mehran R, Huo Y. Han Y, et al. J Am Coll Cardiol. 2014 Jan 7-14;63(1):62-70. doi: 10.1016/j.jacc.2013.09.017. Epub 2013 Sep 26. J Am Coll Cardiol. 2014. PMID: 24076297 Clinical Trial.
Intravenous hydration (with or without rosuvastatin) should remain the cornerstone of the prevention of contrast-induced acute kidney injury in patients with diabetes and chronic kidney disease.
Cecere N, Jadoul M, Labriola L. Cecere N, et al. J Am Coll Cardiol. 2014 Jul 22;64(3):332. doi: 10.1016/j.jacc.2014.02.614. J Am Coll Cardiol. 2014. PMID: 25034074 No abstract available.